Leukemia, Mast-Cell: Clinical Trials

21 trials for Leukemia, Mast-Cell, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed, 3 terminated, 1 active not recruiting, 1 not yet recruiting. 21 Phase 2, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 221Completed 14, Terminated 3, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Withdrawn 1
Phase 15Completed 3, Terminated 1, Withdrawn 1

Follow Leukemia, Mast-Cell: new trials by email Literature Review of Leukemia, Mast-Cell trials Research Report on Leukemia, Mast-Cell

Trials (filtered) newest first · largest first

All 21 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia
Phase 2Not yet recruitingFred Hutchinson Cancer Center522027-01-012026-09-14
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
bezuclastinib - Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN)
Phase 2RecruitingCogent Biosciences, Inc.1402021-11-092026-09-15
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
GTB-3550 TriKE® Phase I, GTB-3550 TriKE® Phase II - High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia
Phase 1 / Phase 2TerminatedGT Biopharma, Inc.122020-01-012022-11-10
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Total-Body Irradiation, Thiotepa, Fludarabine - Acute Biphenotypic Leukemia, Acute Leukemia
Phase 2Active not recruitingFred Hutchinson Cancer Center452019-08-292026-09-25
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Avapritinib - Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis
Phase 2CompletedBlueprint Medicines Corporation1072018-11-212026-10-20
Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
Ibrutinib - Aggressive Systemic Mastocytosis, Mast Cell Leukemia
Phase 2TerminatedJason Robert Gotlib42015-03-012018-09-20
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Brentuximab vedotin - Aggressive Systemic Mastocytosis, Mast Cell Leukemia
Phase 2CompletedJason Robert Gotlib102013-09-012019-01-29
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Phase 2CompletedWake Forest University Health Sciences162011-01-012018-09-07
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
donor natural killer cell infusion - Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Phase 1 / Phase 2CompletedAsan Medical Center472009-01-012013-02-20
Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
Midostaurin (PKC412) - Leukemia
Phase 2CompletedNovartis Pharmaceuticals1162008-10-132018-11-15
Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
darbepoetin alfa, epoetin alfa, fatigue assessment and management - Anemia, Leukemia
Phase 2CompletedMayo Clinic2392007-05-012017-02-10
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
sunitinib malate - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Phase 2TerminatedNational Cancer Institute (NCI)142006-09-012014-05-28
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
Total lymphoid irradiation, Rituximab, Anti-thymoglobulin, rabbit (ATG, rabbit ATG) - Leukemia, Mast-Cell, Mantle-cell Lymphoma
Phase 2CompletedStanford University362005-06-012017-11-28
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
Midostaurin - Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell
Phase 2CompletedJason Robert Gotlib262005-03-012018-09-20
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
alemtuzumab, total-body irradiation, fludarabine phosphate - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Phase 2CompletedFred Hutchinson Cancer Center122005-03-012017-05-30
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
Ontak (Denileukin Diftitox) - Leukemia, Systemic Mastocytosis
Phase 2CompletedM.D. Anderson Cancer Center82004-07-012012-02-08
Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer
anti-thymocyte globulin, busulfan, fludarabine phosphate - Leukemia, Myelodysplastic Syndromes
Phase 2CompletedAsan Medical Center522003-01-012013-03-26
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
PS-341, Doxil, Velcade - Breast Cancer, Leukemia
Phase 1 / Phase 2CompletedUNC Lineberger Comprehensive Cancer Center1072001-05-012012-05-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Imatinib mesylate - Life Threatening Diseases
Phase 2CompletedNovartis Pharmaceuticals1852001-02-012016-11-18
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
total-body irradiation, fludarabine phosphate, cyclosporine - Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Phase 1 / Phase 2CompletedFred Hutchinson Cancer Center212000-05-012020-01-21

Showing 20 of 21. Sign in to see all of them.

Narrower conditions

Leukemia, Myeloid, Acute (11)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (11)  ·  Leukemia, Biphenotypic, Acute (10)  ·  Burkitt Lymphoma (9)  ·  Leukemia (8)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (8)  ·  Leukemia, Myelomonocytic, Chronic (8)  ·  Lymphoma, Mantle-Cell (8)  ·  Mastocytosis, Systemic (8)  ·  Multiple Myeloma (8)  ·  Myeloproliferative Disorders (8)  ·  Hodgkin Disease (7)  ·  Immunoblastic Lymphadenopathy (7)  ·  Leukemia, Hairy Cell (7)

Broader conditions

Hemic and Lymphatic Diseases (21)  ·  Mast Cell Activation Disorders (21)  ·  Neoplasms by Histologic Type (21)  ·  Hematologic Diseases (20)  ·  Immune System Diseases (20)  ·  Neoplasms (20)  ·  Leukemia, Myeloid (19)  ·  Mastocytosis (19)  ·  Bone Marrow Diseases (13)  ·  Immunoproliferative Disorders (13)  ·  Leukemia (13)  ·  Lymphatic Diseases (13)  ·  Mastocytosis, Systemic (13)  ·  Chronic Disease (11)  ·  Disease Attributes (11)

Interventions

Whole-Body Irradiation (4)  ·  fludarabine phosphate (4)  ·  Cyclosporine (3)  ·  Mycophenolic Acid (3)  ·  Busulfan (2)  ·  Cyclophosphamide (2)  ·  Methotrexate (2)  ·  Peripheral Blood Stem Cell Transplantation (2)  ·  Therapeutics (2)  ·  fludarabine (2)  ·  midostaurin (2)  ·  Acetaminophen (1)  ·  Alemtuzumab (1)  ·  Antilymphocyte Serum (1)  ·  Biopsy (1)

Sponsors

Fred Hutchinson Cancer Center (4)  ·  Jason Robert Gotlib (3)  ·  Asan Medical Center (2)  ·  M.D. Anderson Cancer Center (2)  ·  Novartis Pharmaceuticals (2)  ·  Blueprint Medicines Corporation (1)  ·  Cogent Biosciences, Inc. (1)  ·  GT Biopharma, Inc. (1)  ·  Mayo Clinic (1)  ·  National Cancer Institute (NCI) (1)  ·  Stanford University (1)  ·  UNC Lineberger Comprehensive Cancer Center (1)  ·  Wake Forest University Health Sciences (1)

Countries

United States (17)  ·  Italy (4)  ·  Austria (3)  ·  Canada (3)  ·  France (3)  ·  Germany (3)  ·  Netherlands (3)  ·  Norway (3)  ·  Poland (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Belgium (2)  ·  South Korea (2)  ·  Spain (2)  ·  Denmark (1)

Top investigators

Jason Gotlib (2)  ·  Kyoo H. Lee, MD (2)  ·  Brenda Sandmaier (1)  ·  Charles L. Loprinzi, M.D. (1)  ·  David Maloney (1)  ·  David Miklos (1)  ·  Elizabeth C. Dees, MD (1)  ·  Jason Robert Gotlib (1)  ·  Jorge Cortes, MD (1)  ·  Marie Bleakley (1)  ·  Mark B Juckett, MD (1)  ·  Mary Ann Knovich, MD (1)  ·  Michael Heinrich, MD (1)  ·  Patrick Chaftari, MD (1)

Results publications

PMID 27355533, PMID 18327587, PMID 19451433, PMID 21523798, PMID 22563089, PMID 28744009, PMID 31350306, PMID 32437738, PMID 32499241, PMID 33049057, PMID 34873345, PMID 35640224, PMID 35790816, PMID 39649724, PMID 41604606

NIH funding

P30CA015704 (3), P01CA018029 (2), 2008 (1), 2017 (1), N01CM62202 (1), P01CA049605 (1), P01CA078902 (1), P30CA015083 (1), P30CA124435 (1)